Joining Forces to Advance Treatments for Neurodegenerative Diseases
Inhibikase’s business model is two-pronged: demonstrating clinical proof-of-concept in target populations while simultaneously developing first-in-class and best-in-class medications. We intend to commercialize our novel medications, either alone or in partnership, to achieve the best outcome for patients on the shortest timescale possible.
In meeting our primary commitment to patients with neurodegenerative diseases that have little to no treatment options, we collaborate with academic research teams and other third parties to drive our discovery efforts and advance the product candidates in our pipeline.
We currently have ongoing collaborations with The Johns Hopkins University, Memorial Sloan-Kettering Cancer Center, the Medical College of Wisconsin and Arizona State University.